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14.50 and 69.07 ± 8.28 years, and average length of stay for 9.41 ± 4.45 and 9.17 ± 
4.55 days, respectively. Most procedures were conducted at medical centers (45.52% 
and 37.57%). The most frequent diagnoses for THR are avascular necrosis (45.22%) 
and osteoarthritis (44.05%); while for TKR is osteoarthritis (96.42%). Only 40 THR 
(3.90%) and 160 TKR (6.66%) had ever been prescribed antithrombotic agents after 
surgeries, and mostly used aspirin alone (18 THR and 95 TKR). CONCLUSIONS: 
According to this nationwide individual patient dataset, antithrombotic agents are not 
commonly used after THR and TKR in Taiwan, but aspirin is the most frequently 
prescribed of all. These ﬁ ndings deviate from the recommendations of current inter-
national guidelines. To establish Taiwanese own guidance, it is necessary to further 
investigate the effectiveness and safety of prophylactic antithrombotic agents after 
THR and TKR, and explore the inﬂ uences of reimbursement policy and genetic factors 
on these outcomes. 
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OBJECTIVES: To assess the knowledge and perception of community pharmacists in 
Malaysia toward reporting of adverse drug reactions (ADRs). METHODS: A cross-
sectional study employing pre and post intervention design was undertaken with a 
sample of 42 community pharmacists to explore their knowledge of and the perception 
toward the pharmacovigilance and ADRs reporting. Changes in scores before and 
after the completion training program in knowledge and perception were measured. 
Statistical analysis: The data were analyzed by using SPSS version 17.0 software 
package (SPSS Inc., Chicago, IL, USA). Both descriptive and inferential statistics were 
used when ever appropriate. Frequencies and percentages were used to describe the 
respondents’ demographic information and professional characteristics. Wilcoxon 
Signed ranks test, Paired sample t test and The McNemar χ2 test were applied to 
compare the differences in knowledge and perception before and after the educational 
program whenever appropriate. RESULTS: Forty-two community pharmacists (CPs) 
were enrolled in this study. A comparison of CPs knowledge before and immediately 
after implementation the education program showed signiﬁ cant differences, the par-
ticipated community pharmacists’ mean scores in knowledge of pharmacovigilance 
and adverse drug reactions reporting signiﬁ cantly increased compared to the baseline 
(z = −5458, N = 42 P < 0.001). Following the intervention, only few (3, 7.2%) 
respondents reported that they do not have any ideas on how to report ADR to the 
relevant authorities in Malaysia. Upon completion of the education program, a large 
proportion of the pharmacists (45%) believed that they were conﬁ dent in their knowl-
edge in detection and performing ADRs reporting (z = −2.866, N = 42, P = 0.004). 
CONCLUSIONS: The ﬁ nding of the study indicates the need for designing educational 
programs for the community pharmacists, in order to improve the level of knowledge 
toward the pharmacovigilance and ADRs reporting process locally. 
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OBJECTIVES: To assess the cost-effectiveness of T-TTFC compared with L-LTFC 
treatment sequences for patients with open angle glaucoma or ocular hypertension 
(OHT) using a payer perspective in Malaysia and India. METHODS: A Markov model 
simulated the disease progression of open angle glaucoma and ocular hypertension 
(OHT) patients in India and Malaysia. Transition probabilities were obtained from 
Denis (2008), and extrapolated from two phase III clinical trials (Topouzis, 2007; 
Netland; 2001). Probabilities to develop new visual ﬁ eld defect (VFD) was estimated 
from literature (Denis, 2004). Utilization patterns were derived from local hospitals 
and literature. Unit costs were obtained from list prices. The time horizon was 5 years 
and sensitivity analyses were performed on key parameters. RESULTS: At 5 years, 
fewer T-TTFC patients switched to third line treatment, and 65.5% of patients showed 
no disease progression (no new VFDs) compared to 61.4% for L-LTFC Thus initiation 
of treatment in an OHT patient with T followed by TTFC if needed would avoid one 
incidence of VFD in every 24 incident cases (Number Needed to Treat—NNT). In 
Malaysia, T-TTFC results in a cost-savings of 1286 RM (US$378) against L-LTFC. 
In India over a 5-year period, T-TTFC results in a cost savings of 11,184 INR 
(US$243) against L-LTFC. Sensitivity analyses have demonstrated the robustness of 
these ﬁ nding. CONCLUSIONS: From the payer perspective, T-TTFC yielded cost-
savings and fewer treatment switches. Poor IOP control results in therapy changes and 
increases the probability of patients experiencing new VFDs (Denis 2004), which in 
turn adversely impacts patient quality of life. Our savings estimates are conservative 
because potential cost savings, as a consequence of fewer ophthalmologist visits, 
particularly for patients who use private healthcare facilities, have not been captured. 
With these ﬁ ndings policy-makers and clinicians should consider the use of T-TTFC 
for glaucoma patients as potential cost-saving medications. 
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OBJECTIVES: Tax-funded system and the social health insurance (SHI) system are 
two main choices for health-care system reform. This research investigates the differ-
ences of health outcome and health expenditure between these two systems. The 
channels of such differences are also valuable for policymaker. We further explore the 
channel via public health and preventive care investment that leads to these differences. 
We are also interested in the impact of ﬁ scal and political decentralization on health 
systems. METHODS: We merge the data from a variety of sources including WHO, 
the World Bank, OECD together with database prepared by independent researchers 
like Polity IV and Government Performance Indicator. After controlling the variables 
indicating the social-economic situations, we implement the Pooled-OLS Method and 
Fix-Effect Method for panel data. Then check the model speciﬁ cation by testing the 
autocorrelation of the residuals. RESULTS: When the share of SHI in public health 
expenditure increases, the total health expenditure (THE) measured as its share in 
GDP increase dramatically. However, if there is local responsibility, this negative 
impact will be mitigated. What’s more, the increase of SHI share also plays down the 
life expectancy, but with local responsibility the negative impact can get amended. It 
is worth the attention that the public health performance, measured by the share of 
expenditure in THE and a series of public health behaviors including the immunization 
rates and infectious disease incidences, presents a consistent pattern. That is, with the 
increase of the SHI share, the public health performance is weakened, but with local 
responsibility, the performance will be improved to some extent. CONCLUSIONS: 
Tax-funded system is more efﬁ cient in the sense of cost-beneﬁ t, and public health and 
preventive care investment are important channels of these different performances 
between the two types of health-care system. 
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OBJECTIVES: The aim of this paper is to investigate whether the adoption of phar-
maceutical innovation increases the overall expenditure on health care by focusing on 
diabetic patients. METHODS: By examining the National Health Insurance sampling 
longitudinal claims data between 2000 and 2004, we use a new class of drugs, namely, 
thiazolidinediones (TZD), as an example to investigate the effect on health expenditure 
of prescribing new drugs to patients by decomposing the impact into treatment sub-
stitution and treatment expansion effects. The difference-in-difference approach was 
used to estimate the effects of adopting new drugs by comparing the difference between 
the users of TZD drugs (the treatment group) and the nonusers of TZD drugs (the 
control group) as well as the difference between the pre and post periods. RESULTS: 
Our results indicate that the introduction of new drugs mainly impacts the outpatient 
drug expenditure and does not give rise to any offsetting effect on other outpatient 
and inpatient health expenditures. This suggests that the adoption of pharmaceutical 
innovation in treating diabetic patients is expenditure-increasing. In addition, we ﬁ nd 
evidence that the treatment substitution channel has a more signiﬁ cant impact on 
health expenditure than the treatment expansion channel. CONCLUSIONS: An 
important policy implication for our ﬁ nding is that new prescription drugs do not pay 
for themselves, suggesting that the justiﬁ cation for increasing health expenditure on 
the treatment of diabetes is not conditional upon a lowering in the demand for other 
types of health-care services. By contrast, it is conditional upon the increased health 
beneﬁ ts per se. 
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OBJECTIVES: The innovative but expensive biologic agents are introduced in recent 
years, Korea government is meeting with difﬁ culty in funding for these agents due to 
limited health-care budget. Pay for performance as risk sharing scheme has been 
adopted to overcome this situation in other countries. In this article we tried to ﬁ nd 
an affordable price based upon a budget neutral concept and adapted to risk sharing 
of Omalizumab. METHODS: Omalizumab, for treatment of moderate to severe 
allergic asthma, is only treated for responders at 16 weeks. We modeled the perfor-
mance-based risk sharing along four assumptions: 1) no additional national health-
care budget, budget of risk sharing ≤ budget of no risk sharing; 2) positive 
manufacturer’s proﬁ t; 3) reimbursed only for responders at 16 weeks; and 4) manu-
facturer funding to responder in screening period. We also simulated the model by 
changing of input parameters. RESULTS: We deﬁ ned and analyzed the function of 
risk sharing scheme based on national health-care budget and manufacturer’s proﬁ t. 
Lower boundary of affordable price was derived from the minimum of acceptable 
predicted sales volume for manufacturer and upper was calculated by a point of budget 
neutral. Lower boundary was highly depends on unit selling price, production cost 
